News
DARE
3.565
-7.04%
-0.270
Dare Bioscience Q3 2024 Earnings Preview
Seeking Alpha · 1d ago
Insights into Dare Bioscience's Upcoming Earnings
Benzinga · 1d ago
Dare Bioscience announces grant to develop non-hormonal contraceptive candidate
TipRanks · 1d ago
Daré Bioscience Announces It Entered Into A Grant Agreement With The Bill & Melinda Gates Foundation For A Grant Of Up To ~$10.7M To Fund Activities Related To The Identification And Development Of A Novel Non-Hormonal Intravaginal Contraceptive Product Candidate And To Add Additional Clinical Sites To Accelerate The Ongoing Ovaprene Pivotal Study
Benzinga · 1d ago
DARÉ BIOSCIENCE ANNOUNCES GRANT TO SUPPORT DEVELOPMENT OF A NOVEL NON-HORMONAL CONTRACEPTIVE CANDIDATE AND EXPANSION OF OVAPRENE® PIVOTAL STUDY CLINICAL TRIAL SITES
Reuters · 1d ago
Weekly Report: what happened at DARE last week (1104-1108)?
Weekly Report · 3d ago
Fortrea Holdings Inc. (FTRE) Lags Q3 Earnings Estimates
NASDAQ · 6d ago
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know
NASDAQ · 11/07 17:00
Weekly Report: what happened at DARE last week (1028-1101)?
Weekly Report · 11/04 10:10
Weekly Report: what happened at DARE last week (1021-1025)?
Weekly Report · 10/28 10:06
Daré Bioscience Enhances Investor Engagement with New Presentation
TipRanks · 10/25 12:31
Dare Bioscience Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 10/24 10:43
Daré Bioscience: Strategic Funding and Promising Pipeline Drive Buy Rating
TipRanks · 10/24 10:29
Daré Bioscience Secures Funding for HPV Treatment
TipRanks · 10/23 16:57
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Barchart · 10/23 11:30
Daré Bioscience Secures $15M Funding through Stock Agreement
TipRanks · 10/21 21:28
Dare Bioscience announces common stock purchase agreement fo up to $15M
TipRanks · 10/21 12:32
Daré Bioscience enters into $15M stock purchase agreement
Seeking Alpha · 10/21 12:17
DARE BIOSCIENCE - LPC AGREED NOT TO CAUSE OR ENGAGE IN ANY DIRECT OR INDIRECT SHORT SELLING OR HEDGING OF CO'S COMMON STOCK
Reuters · 10/21 12:05
Press Release: Daré Bioscience Announces Common -2-
Dow Jones · 10/21 12:05
More
Webull provides a variety of real-time DARE stock news. You can receive the latest news about Dare Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.